Upgrade to SI Premium - Free Trial

MetaVia (MTVA)

2.57 +0.12 (4.90%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (2/9/26 *Est.)

Latest Headlines

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference June 4, 2026 8:31 AM - PR NewsWire Form 8-K MetaVia Inc. For: May 27 May 27, 2026 9:01 AM - SEC Filing MetaVia reports 9.1% weight loss in obesity drug trial May 27, 2026 8:31 AM - StreetInsider MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH May 27, 2026 8:31 AM - PR NewsWire MetaVia announces peer-reviewed study on vanoglipel for liver fibrosis May 20, 2026 8:02 AM - StreetInsider MetaVia Highlights Peer-Reviewed Publication Supporting the Anti-Fibrotic Potential of Vanoglipel in MASH May 20, 2026 8:00 AM - PR NewsWire Form 8-K MetaVia Inc. For: May 18 May 18, 2026 9:01 AM - SEC Filing MetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions May 18, 2026 8:31 AM - PR NewsWire Form SCHEDULE 13G MetaVia Inc. Filed by: Alyeska Investment Group, L.P. May 15, 2026 4:45 PM - SEC Filing Form 10-Q MetaVia Inc. For: Mar 31 May 14, 2026 4:09 PM - SEC Filing Form 8-K MetaVia Inc. For: May 14 May 14, 2026 4:07 PM - SEC Filing MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update May 14, 2026 4:05 PM - PR NewsWire Form 8-K MetaVia Inc. For: May 11 May 11, 2026 9:01 AM - SEC Filing MetaVia to Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026 May 11, 2026 8:31 AM - PR NewsWire Form ARS MetaVia Inc. For: Dec 31 April 27, 2026 6:06 AM - SEC Filing Form DEF 14A MetaVia Inc. For: Jun 08 April 27, 2026 6:04 AM - SEC Filing Form PRE 14A MetaVia Inc. For: Jun 08 April 15, 2026 4:02 PM - SEC Filing Form 8-K MetaVia Inc. For: Apr 10 April 10, 2026 8:46 AM - SEC Filing MetaVia begins higher-dose phase 1 trial of obesity drug DA-1726 April 10, 2026 8:30 AM - StreetInsider MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity April 10, 2026 8:30 AM - PR NewsWire Form 424B3 MetaVia Inc. April 7, 2026 4:02 PM - SEC Filing Form EFFECT MetaVia Inc. April 7, 2026 12:34 PM - SEC Filing Form S-8 MetaVia Inc. April 3, 2026 4:04 PM - SEC Filing Form POS AM MetaVia Inc. April 3, 2026 4:01 PM - SEC Filing MetaVia (MTVA) PT Lowered to $20 at H.C. Wainwright March 30, 2026 6:45 AM - StreetInsider MetaVia (MTVA) PT Lowered to $20 at H.C. Wainwright March 27, 2026 12:18 PM - StreetInsider Form 8-K MetaVia Inc. For: Mar 26 March 26, 2026 4:31 PM - SEC Filing Form 10-K MetaVia Inc. For: Dec 31 March 26, 2026 8:47 AM - SEC Filing Form 8-K MetaVia Inc. For: Mar 26 March 26, 2026 8:31 AM - SEC Filing MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update March 26, 2026 8:31 AM - PR NewsWire Form 8-K MetaVia Inc. For: Mar 18 March 18, 2026 8:06 AM - SEC Filing MetaVia receives IRB approval for higher-dose obesity drug trial March 18, 2026 8:01 AM - StreetInsider MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and G March 18, 2026 8:01 AM - PR NewsWire Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing March 13, 2026 8:35 AM - StreetInsider MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035 March 12, 2026 9:02 AM - PR NewsWire Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th March 10, 2026 10:22 AM - StreetInsider Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th March 10, 2026 10:21 AM - Globe NewsWire Full Article List